Technical Data
M3885-59C
MHC Class 1, H2, Db, alpha3 (Biotin)
Description:
MHC Class I molecules are histocompatibility antigens encoded by the H-2 gene complex and consist of heterodimers of highly polymorphic alpha chains noncovalently associated with the invariant beta2-microglobulin (3,4). These antigens are expressed on most nucleated cells but expression varies on different cell types. MHC Class I molecules present endogenously synthesized peptides to CD8+ T lymphocytes, which are usually cytotoxic T cells (5). MHC Class I antigens expressed on thymic epithelial cells regulate the positive and negative selection of CD8+ T cells during T cell ontogeny (3,6). This antibody binds to the alpha3 domain of H-2Db in the presence or absence of beta2 microglobulin (7,8).

Applications:
Suitable for use in Flow Cytometry, Immunoprecipitation and Complement-mediated cytotoxicity studies. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: 1ug/10e6 cells
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2a,k28-14-8Purified
SizeStorageShippingSourceHost
500ug-20°CBlue IceMouseMouse
Concentration:
~0.5mg/ml
Immunogen:
C3H.SW mouse splenocytes
Purity:
Purified
Form
Supplied as a liquid in PBS, 0.1% sodium azide. Labeled with Biotin.
Specificity:
Recognizes an epitope in the alpha3 domain of mouse H-2Db. Crossreacts with the alpha3 domain of H-2Ld, but not Kd or Dd, and with H-2Dq and/or Lq. Antibody has been shown to block H-2Ld-specific and H-2Ld-restricted antigen-specific lysis of target cells by cytotoxic T lymphocytes, but it does not block recognition of H-2Ld-positive target cells by Ly-6G2-positive NK cells.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Ozato, K., et al., J. Immunol. 125: 2473 (1980). 2. Ozato, K. & Sachs, D.H., J. Immunol. 126: 317 (1981). 3. Lawlor, D.A., et al., Annu. Rev. Immunol. 8: 23 (1990). 4. Bjorkman, P.J., et al., Nature 329: 506 (1987). 5. Yewdell, J.W. & Bennett, J.R., Cell 62: 203 (1990). 6. Zijlstra, M., et al., Nature 344: 742 (1990). 7. Allen, H., et al., Nature 309: 279 (1984). 8. Allen, H., et al., Proc. Natl. Acad. Sci. USA 83: 7447 (1986). 9. Woodward, J.G., et al., Proc. Natl. Acad. Sci. USA 79: 3613 (1982). 10. Orn, A., et al., Nature 297: 415 (1982). 11. Kundig, T.M., et al., Science 268: 1343 (1995). 12. Mason, L.H., et al., J. Exp. Med. 182: 293 (1995). 13. Gri, G., et al., Cancer Res. 62: 4390 (2002).